Synaptogenix Inc (SNPX)

[Cyosol]

I doubt that. Even Dr. Ryan has talked about starting a pivotal P3 trial, so I assume they'll get that one going and maybe a bioequivalence study at the same time. Then if everything works out as expected, I'm guessing it won't hit markets until 2021, even if the FDA does slap some breakthrough therapy label on it.

As I've said before, I believe the top-line data in a few weeks will be a milestone, not the finish line. Some may disagree and will sell their shares on day one. Personally I'm more interested in waiting another year or two to see what this company is really capable of once the warrants are cashed in and they can afford to pursue several indications at once.

Safety and optimal dose has already been confirmed, so they could immediately start with phase 2b trials for any additional indications.